Takeda Closes Deal With Ovid for Soticlestat

Takeda Closes Deal With Ovid for Soticlestat

294990

Takeda Closes Deal With Ovid for Soticlestat

Ovid Therapeutics has closed an agreement under which Takeda Pharmaceuticals will secure global rights to develop and market the investigational oral therapy soticlestat (previously TAK-935/OV935) for two rare epilepsy syndromes, one of which is Dravet syndrome, the company announced. Takeda had announced the exclusive agreement in early March. With its closing, Takeda now is solely responsible for further development and commercialization of soticlestat, worldwide. This includes initiating a Phase 3 clinical trial of soticlestat in children…

You must be logged in to read/download the full post.